

Angola Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Angola			
2. Grant number(s): 19-AGO-25c-X/ 15-AGO-08h-Y			
3. Date of Decision Letter: March 8 th , 2019			
4. Date of the Partnership Framework Agreement: October 4, 2013			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, Liquid.			
8. Programme duration²: 2015 - 2019			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2020 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2018 ³	2019	Total ⁴
Routine Programme (US\$)	US\$1,407,576	US\$1,686,500	US\$3,094,076
10. Vaccine introduction grant: Not applicable			
This vaccine was introduced in the country and the vaccines introduction grant was disbursed on 7/7/2015 for US\$:785,500.			
11. Product switch grant: Not Applicable			
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁵			
Number of vaccines to be purchased with Gavi funds	2015-2018	2019	
IPV Routine Programme (doses)		744,200	

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the total amount endorsed by Gavi for 2015 to 2018.

⁵ This is the amount that Gavi has approved.

Annual Amounts (US\$)	US\$1,407,576	US\$1,686,500
13. Procurement agency: UNICEF		
14. Self-procurement: Not Applicable.		
15. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Angola is encouraged to contribute to vaccine and/or supply costs for IPV.		
16. Operational support for catch-up campaigns: Not applicable.		
17. Additional reporting requirements:		
Reports and other information	Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		
1. vaccine stock levels including buffer stock, by end of March;	31 March 2019	
2. Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.	15 May 2019	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
18. Financial clarifications*: Country shall provide the following clarifications to Gavi: Not applicable		
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>		

19. Other conditions:

Insurance: According to Gavi grant management requirements. The Ministry of Health will be responsible for all program assets (including vaccines and related supplies, cold chain equipment and other tangible assets (to be procured through UN agencies) at both central and regional levels depending on the size of the program. Availability of the budget: If possible and at reasonable cost, the Ministry of Health will have to take out all-risk insurance and general liability insurance with reputable and strong insurance companies by choosing a cover corresponding to the policies held by similar organizations that carry out comparable activities, otherwise the Ministry of Health will have to provide a budget line to supply the replacement of damaged or missing vaccines or assets.

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Angola envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Angola.

On behalf of Gavi

Signed by,



Hind Khatib-Othman
Managing Director, Country Programmes
March 8th, 2019